Japan Influenza Vaccine Market Size & Outlook, 2024-2030
- Pharmaceuticals
- Vaccines
- Influenza Vaccine Market Outlook
- Vaccines
Global Market
Related Markets
Ask a question about the influenza vaccine market
Japan influenza vaccine market highlights
- The Japan influenza vaccine market generated a revenue of USD 249.7 million in 2023 and is expected to reach USD 397.2 million by 2030.
- The Japan market is expected to grow at a CAGR of 7% from 2024 to 2030.
- In terms of segment, inactivated was the largest revenue generating vaccine type in 2023.
- Inactivated is the most lucrative vaccine type segment registering the fastest growth during the forecast period.
Influenza vaccine market data book summary
| Market revenue in 2023 | USD 249.7 million |
| Market revenue in 2030 | USD 397.2 million |
| Growth rate | 7% (CAGR from 2024 to 2030) |
| Largest segment | Inactivated |
| Fastest growing segment | Inactivated |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Inactivated, Live Attenuated |
| Key market players worldwide | GSK PLC, Pfizer Inc, Merck & Co Inc, Viatris Inc, AstraZeneca PLC, Sinovac Biotech Ltd, CSL Ltd, Emergent BioSolutions Inc, Vaxess Technologies, Osivax, Emergex Vaccines |
Other key industry trends
- In terms of revenue, Japan accounted for 3.2% of the global influenza vaccine market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Asia Pacific, China influenza vaccine market is projected to lead the regional market in terms of revenue in 2030.
- India is the fastest growing regional market in Asia Pacific and is projected to reach USD 477.8 million by 2030.
Japan is one of the most technologically advanced countries in Asia Pacific. Its influenza vaccine market is expected to grow rapidly over the forecast period owing to high government spending to reduce the flu burden. Multiple initiatives, such as government grants to various research institutes and companies, can help develop practical solutions for the influenza burden in the country.
Similarly, in October 2022, the Government of Japan started preparations against the flu and COVID-19. Under these preparations, the government recommended people get vaccinated against the flu if they notice any symptoms.
Furthermore, several organic and inorganic initiatives undertaken by leading participants to strengthen their presence are driving the country’s market. For instance, in November 2022, Shionogi & Co., Ltd. announced that it applied for the approval of S-268019, a protein-based vaccine for use as a booster dose against COVID-19.
No credit card required*
Publish Date: Dec 15, 2025
Customize the Report
20% free customization
- Include
- Countries, segments, points
- Tailor
- To your product definition
- Extend
- Deeper competitor detail
- Or
- A fully bespoke study
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Influenza Vaccine Market Scope
Influenza Vaccine Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Pfizer Inc | View profile | 88,000 | 66 Hudson Boulevard East, New York, NY, United States, 10001-2192 | www.pfizer.com |
| Merck & Co Inc | View profile | 72,000 | 126 East Lincoln Avenue, Rahway, NJ, United States, 07065 | www.merck.com |
| GSK PLC | View profile | 70,200 | 980 Great West Road, Brentford, Middlesex, United Kingdom, TW8 9GS | www.gsk.com |
| AstraZeneca PLC | View profile | 89,900 | 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, United Kingdom, CB2 0AA | www.astrazeneca.com |
| Viatris Inc | View profile | 38,000 | 1000 Mylan Boulevard, Canonsburg, PA, United States, 15317 | www.viatris.com |
| Sinovac Biotech Ltd | View profile | 3,261 | No.39, Shangdi Xi Road, Haidan District, Beijing, China, People's Republic of, 100085 | www.sinovac.com |
| CSL Ltd | View profile | 32,000 | 655 Elizabeth Street, Melbourne, VIC, Australia, 3000 | www.csl.com |
| Emergent BioSolutions Inc | View profile | 1,600 | 300 Professional Drive, Gaithersburg, MD, United States, 20879 | www.emergentbiosolutions.com |
| Vaxess Technologies | View profile | 51-100 | Cambridge, Massachusetts, United States, North America | www.vaxess.com |
| Osivax | View profile | 11-50 | Lyon, Rhone-Alpes, France, Europe | www.osivax.com/ |
Japan Influenza Vaccine Market Outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Influenza Vaccine Market Outlook will help companies and investors design strategic landscapes.
Inactivated was the largest segment with a revenue share of 97.48% in 2023.
Horizon Databook has segmented the Japan influenza vaccine market based on inactivated, live attenuated covering the revenue growth of each sub-segment from 2018 to 2030.
Japan is one of the most technologically advanced countries in Asia Pacific. Its influenza vaccine market is expected to grow rapidly over the forecast period owing to high government spending to reduce the flu burden. Multiple initiatives, such as government grants to various research institutes and companies, can help develop practical solutions for the influenza burden in the country.
Similarly, in October 2022, the Government of Japan started preparations against the flu and COVID-19. Under these preparations, the government recommended people get vaccinated against the flu if they notice any symptoms.
Furthermore, several organic and inorganic initiatives undertaken by leading participants to strengthen their presence are driving the country’s market. For instance, in November 2022, Shionogi & Co., Ltd. announced that it applied for the approval of S-268019, a protein-based vaccine for use as a booster dose against COVID-19.
- Japan Influenza Vaccine Market Vaccine Type Outlook (Revenue, USD Million , 2018-2030)
- Inactivated
- Live Attenuated
- Japan Influenza Vaccine Market Indication Outlook (Revenue, USD Million , 2018-2030)
- Quadrivalent
- Trivalent
- Japan Influenza Vaccine Market Age Group Outlook (Revenue, USD Million , 2018-2030)
- Pediatric
- Adult
- Japan Influenza Vaccine Market Route of Administration Outlook (Revenue, USD Million , 2018-2030)
- Injection
- Nasal Spray
- Japan Influenza Vaccine Market Distribution Channel Outlook (Revenue, USD Million , 2018-2030)
- Hospitals & Pharmacy
- Government & Institutional supply
- Other Distribution Channels
Reasons to subscribe to Influenza Vaccine Market Outlook databook
- Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
- Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
- Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
- Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
- Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Influenza Vaccine Market Outlook databook
- Our clientele includes a mix of Influenza Vaccine Market Outlook companies, investment firms, advisory firms & academic institutions.
- 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
- Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
- The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Japan Influenza Vaccine Market Outlook, including forecasts for subscribers. This country databook contains high-level insights into Japan Influenza Vaccine Market Outlook from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Japan Influenza Vaccine Market, 2018-2030 (US$M)
Japan influenza vaccine market statistics, by vaccine type, 2018-2030 (US$M)
